Targets › IL6ST
1 program from 1 company in 6 trials: 3 Phase 3, 2 Phase 2, 1 Phase 4; Neurology, Immunology; next expected readout Nov 2026.
Functions as a shared signal-transducing subunit not only for IL6 but also for other cytokine receptor complexes, including IL6, LIF, OSM, CNTF, IL11, CTF1, BSF3, MT-RNR2/humanin, CLCF1 and the heterodimeric complex CRLF1-CLCF1. Engages site 2 of CNTF, CLCF1, LIF, and IL-6, and site 3 of IL27 and IL6. (UniProt, P40189)
Open in Phaseline: the race on IL6ST, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Satralizumab IL6Ralpha/GP130 antagonist | IL6R, IL6ST | Phase 3 | NMDAR Autoimmune Encephalitis; Neuromyelitis Optica Spectrum Disorder; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Duchenne Muscular Dystrophy … | Nov 2026 |
NMDAR Autoimmune Encephalitis (1) Neuromyelitis Optica Spectrum Disorder (1) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) (1) Duchenne Muscular Dystrophy (1) NMOSD (1) Facioscapulohumeral Muscular Dystrophy 1 (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.